Bayer, Thomas A., Prof. Dr.

Professor of Molecular Psychiatry

• 1984-1989 Diploma in biology, University of Stuttgart and Whitney Lab Florida
• 1989-1993 PhD at the University of Cologne (PhD Thyssen Graduate School)
• 1993 Postdoctoral Research Fellow, University of Cologne, Cologne
• 1993-1997 Postdoctoral Research Fellow, Institute of Neuropathology, University of Bonn Medical Center, Bonn
• 1997-2002 Lab leader, Department of Psychiatry, University of Bonn Medical Center, Bonn
• 2002-2007 Head of Neurobiology Lab, University of Saarland Medical Center, Homburg
• 2004 Appointment to apl Professor at the University Medical Center Saarland
• 2007-present University Professor in “Molecular Psychiatry” at the University of Göttingen, University Medical Center Göttingen
• 2006-2011 Coordinator of the European Commission funded International Alzheimer PhD School «Neurodegeneration in Alzheimer’s disease – mechanism, consequence and therapy»

Major Research Interests

Pathogenesis of Alzheimer’s disease, neuronal cell death mechanisms, preclinical proof-of-concept studies; characterization and development of mouse models for Alzheimer’s disease (neuropathology, anatomy, biochemistry, behavioral tests), preclinical therapy studies in mouse models, vaccine and passive immunization against Alzheimer’s disease.


Homepage Department/Research Group

https://psychiatrie.umg.eu/forschung/professuren/molekulare-psychiatrie/


Selected Recent Publications
Reviews:

• Bayer TA (2021). N-Truncated Aβ Starting at Position Four — Biochemical Features, Preclinical Models, and Potential as Drug Target in Alzheimer’s disease. Frontiers in Aging Neuroscience 13, 710579
• Bayer TA (2022). Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease. Molecular Psychiatry 27, 1880-1885

Original Papers:

• Bouter, Y., Kacprowski, T., Rossler, F., Jensen, L.R., Kuss, A.W., and Bayer, T.A., (2020). miRNA Alterations Elicit Pathways Involved in Memory Decline and Synaptic Function in the Hippocampus of Aged Tg4-42 Mice. Front Neurosci 14, 580524
• Hinteregger, B., Loeffler, T., Flunkert, S., Neddens, J., Birner-Gruenberger, R., Bayer, T.A., Madl, T., and Hutter-Paier, B., (2020). Transgene integration causes RARB downregulation in homozygous Tg4-42 mice. Sci Rep 10, 6377
• Bakrania, P., Hall, G., Bouter, Y., Bouter, C., Beindorff, N., Cowan, R., Davies, S., Price, J., Mpamhanga, C., Love, E., Matthews, D., Carr, M.D., and Bayer, T.A., (2022). Discovery of a novel pseudo β-hairpin structure of N-truncated amyloid-β for use as a vaccine against Alzheimer’s disease. Molecular Psychiatry 27, 840-848
• Bouter, Y., Liekefeld, H., Pichlo, S., Westhoff, A.C., Fenn, L., Bakrania, P., and Bayer, T.A., (2022). Donanemab detects a minor fraction of amyloid-β plaques in post-mortem brain tissue of patients with Alzheimer’s disease and Down syndrome. Acta Neuropathologica 143, 601-603